Home NDC 73625-113 CAMZYOS
Product NDC 73625-113
11-digit product format 736250113
Labeler code 73625
Product ID 73625-113_bfa802de-cde9-46d7-a1f1-46edb30d7c9a
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name mavacamten
Dosage form CAPSULE, GELATIN COATED
Route ORAL
Labeler Myokardia, Inc.
Application NDA214998
Marketing category NDA
Marketing start 2022-04-28
Substance MAVACAMTEN
Active strength 10 mg/1
Pharmacologic classes Cardiac Myosin Inhibitor [EPC], Cardiac Myosin Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 5 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N214998-001 CAMZYOS MAVACAMTEN 2.5MG CAPSULE / ORAL RLD 2022-04-28 N214998-002 CAMZYOS MAVACAMTEN 5MG CAPSULE / ORAL RLD, RS 2022-04-28 N214998-003 CAMZYOS MAVACAMTEN 10MG CAPSULE / ORAL RLD 2022-04-28 N214998-004 CAMZYOS MAVACAMTEN 15MG CAPSULE / ORAL RLD 2022-04-28 N214998-005 CAMZYOS MAVACAMTEN 1MG CAPSULE / ORAL RLD 2026-09-30
Orange Book patents# Current patent rows page 1 of 1 · 14 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N214998-001 9585883 2034-06-19 U-3373 2022-05-26 N214998-001 9585883 2034-06-19 U-4632 2022-05-26 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 N214998-002 9585883 2034-06-19 U-3373 2022-05-26 N214998-002 9585883 2034-06-19 U-4632 2022-05-26 N214998-002 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 N214998-003 9585883 2034-06-19 U-3373 2022-05-26 N214998-003 9585883 2034-06-19 U-4632 2022-05-26 N214998-003 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 N214998-004 9585883 2034-06-19 U-3373 2022-05-26 N214998-004 9585883 2034-06-19 U-4632 2022-05-26 N214998-004 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 N214998-005 9585883 2034-06-19 U-4632 2026-10-27 N214998-005 RE50050 2036-04-28 Drug substance, Drug product 2026-10-27
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 18 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 134 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-005 CAMZYOS 1MG CAPSULE / ORAL RLD 2026-09-30 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-005 CAMZYOS 1MG CAPSULE / ORAL RLD 2026-09-30 c2088c7a36db…2026-09-14 22:38:34 2026-08 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 84e616aacf4f…2026-08-18 06:07:40 2026-07 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N214998-003 CAMZYOS 10MG CAPSULE / ORAL RLD 2022-04-28 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N214998-004 CAMZYOS 15MG CAPSULE / ORAL RLD 2022-04-28 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N214998-001 CAMZYOS 2.5MG CAPSULE / ORAL RLD 2022-04-28 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N214998-002 CAMZYOS 5MG CAPSULE / ORAL RLD, RS 2022-04-28 03ed91905a0d…
Observed Orange Book patent history# Patent history page 1 of 7 · 270 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N214998-001 9585883 2034-06-19 U-3373 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-001 9585883 2034-06-19 U-4632 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-002 9585883 2034-06-19 U-3373 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-002 9585883 2034-06-19 U-4632 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-002 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-003 9585883 2034-06-19 U-3373 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-003 9585883 2034-06-19 U-4632 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-003 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-004 9585883 2034-06-19 U-3373 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-004 9585883 2034-06-19 U-4632 2022-05-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-004 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-005 9585883 2034-06-19 U-4632 2026-10-27 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N214998-005 RE50050 2036-04-28 Drug substance, Drug product 2026-10-27 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N214998-001 9585883 2034-06-19 U-3373 2022-05-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-002 9585883 2034-06-19 U-3373 2022-05-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-002 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-003 9585883 2034-06-19 U-3373 2022-05-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-003 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-004 9585883 2034-06-19 U-3373 2022-05-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 N214998-004 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 c2088c7a36db…2026-09-14 22:38:34 2026-08 N214998-001 9585883 2034-06-19 U-3373 2022-05-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-002 9585883 2034-06-19 U-3373 2022-05-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-002 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-003 9585883 2034-06-19 U-3373 2022-05-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-003 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-004 9585883 2034-06-19 U-3373 2022-05-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N214998-004 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 84e616aacf4f…2026-08-18 06:07:40 2026-07 N214998-001 9585883 2034-06-19 U-3373 2022-05-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-002 9585883 2034-06-19 U-3373 2022-05-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-002 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-003 9585883 2034-06-19 U-3373 2022-05-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-003 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-004 9585883 2034-06-19 U-3373 2022-05-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214998-004 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N214998-001 9585883 2034-06-19 U-3373 2022-05-26 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214998-001 RE50050 2036-04-28 Drug substance, Drug product 2024-08-20 011fe1cb6892…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 9 · 342 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base CAMZYOS
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength MAVACAMTEN 10 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination QX45B99R3J Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 8 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2600872 Internal RxNorm lookup 2600878 Internal RxNorm lookup 2600880 Internal RxNorm lookup 2600882 Internal RxNorm lookup 2600884 Internal RxNorm lookup 2600886 Internal RxNorm lookup 2600888 Internal RxNorm lookup 2600890 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 73625-113-11 CAMZYOS 30 in 1 BOTTLE, PLASTIC CAPSULE, GELATIN COATED 30 8
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 73625-113 CAMZYOS (MAVACAMTEN) CAPSULE, GELATIN COATED [MYOKARDIA, INC.] 8 Current NDC, Legacy NDC, 1 package rows 20250501_669c936b-3ee6-4e36-8a22-79dd11b1255b.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Marketing end Sample Exclude flag Status 73625-113-11 73625011311 30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (73625-113-11) 2022-04-28 0000-00-00 No No Current